Effect of Shanzha Xiaozhi Capslue on Stability of Atherosclerosis Plaques in Patients with Metabolic Syndrome and Carotid Atherosclerosis
10.3969/j.issn.1005-5304.2013.09.004
- VernacularTitle:山楂消脂胶囊对代谢综合征并颈动脉硬化患者斑块稳定性的影响
- Author:
Honglei YANG
;
Wenhui WANG
;
Huayun ZHAO
;
Weiqiang CHEN
;
Zhaohong LIU
;
Tong LIANG
- Publication Type:Journal Article
- Keywords:
Shanzha Xiaozhi Capslue;
metabolic syndrome;
carotid atherosclerosis;
carotid intima-media thickness;
stability of atherosclerosis plaques
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2013;(9):10-12
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of Shanzha Xiaozhi Capslue on stability of atherosclerosis plaques in patient with metabolic syndrome (MS) and carotid atherosclerosis (CAS). Methods Totally 106 patients with MS and CAS were randomly divided into 2 groups with 55 cases in the treatment group and 51 cases in the control group. The control group improved the way of life and control of relevant risk factors, while the treatment group was treated with Shanzha Xiaozhi Capslue additionally for 6 months. The occurrence of major adverse cardiovascular and cerebrovascular events of the two groups was compared. The intima-media thickness, plaques grade of carotid artery and the changes of Hs-CRP, Hcy, insulin resistance were measured before and after the treatment. Results After treatment, the occurrence of major adverse cardiovascular and cerebrovascular events in the treatment group reduced significantly compared with the control group (P=0.047). The intima-media thickness and plaques grade of carotid artery in the treatment group decreased significantly compared with the control group (P<0.05), and the serum levels of Hs-CRP, Hcy, insulin resistance were decreased significantly compared with the control group (P<0.01). Conclusion Shanzha Xiaozhi Capslue can decrease the intima-media thickness and plaques score of carotid artery, stabilize atherosclerotic plaque, thus reduce the occurrence of major adverse cardiovascular and cerebrovascular events of patients with MS and CAS.
